Oculis to Highlight Breakthrough Candidates at Goldman Sachs Healthcare Conference
Event summary
- Oculis to present at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026.
- CEO Dr. Riad Sherif to discuss Privosegtor and Licaminlimab in a fireside chat.
- Privosegtor has Breakthrough Therapy and PRIME designations for optic neuritis.
- Licaminlimab is in a registrational trial for dry eye disease as a genotype-based precision medicine.
- Company aims to deliver several pivotal readouts with current funding.
The big picture
Oculis' presentation at the Goldman Sachs conference underscores the strategic importance of its late-stage pipeline in neuro-ophthalmology and ophthalmology. The focus on Privosegtor and Licaminlimab highlights the company's push into high-value, unmet medical needs, particularly in optic neuritis and dry eye disease. The regulatory designations for Privosegtor suggest a favorable path forward, while the genotype-based approach for Licaminlimab positions Oculis at the forefront of precision medicine in ophthalmology.
What we're watching
- Regulatory Momentum
- Whether Privosegtor's Breakthrough Therapy and PRIME designations will accelerate approval timelines.
- Market Potential
- The pace at which Oculis can unlock the $7B+ U.S. market opportunity for optic neuropathies.
- Execution Risk
- How Oculis will manage multiple pivotal readouts with current funding.
Related topics